Use access key #2 to skip to page content.
$9.40 -0.31 (-3.19%)
12/4/2008 4:05 PM

Mylan Laboratories, Inc. (MYL)

CAPS Rating:
*****

The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.

View All Commentary (MYL)

Recs

0

Avatar boiler1111 (96.46) Submitted: 2/22/07 9:40 AM : Outperform Start Price: $20.14 MYL Score: -13.75

Generics will continue to grow share of overall drug market. Not just growth, though, HUGE growth. In fact, by 2010, generics will have 80% share as opposed to <50% just recently. This whole sector will outperform, but I pick MYL as the one with the greatest margin of safety due to: attractive P/E and PEG, solid mgmt, and a divendend. (Yes a div on a generic). Be confident in this sector (generics) and in MYL particularly.

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners

Sponsored Links